Israeli generic drug giant Teva announced Friday that it will provide ten million doses of its anti-malarial drug hydroxychloroquine, which could potentially prove effective in fighting the coronavirus pandemic, to US hospitals free of charge.
The company said six million doses will be delivered to US hospitals by March 31, and more than ten million in a month.
“We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost,” Teva executive vice president Brendan O’Grady said.
US President Donald Trump touted the potential use of chloroquine on Thursday after encouraging results in China and France, although many experts warn of caution.
In France, the Sanofi laboratory said it was ready Tuesday to offer millions of doses of hydroxychloroquine to potentially treat 300,000 patients.
The hydroxychloroquine molecule, also used for decades in autoimmune diseases like lupus or rheumatoid arthritis, could indeed have an effect on the elimination of the virus, said Professor Didier Raoult, director of France’s Institut Hospitalo Universitaire (IHU) for the study of infectious diseases.
According to the study carried out by Prof. Raoult on 24 patients with coronavirus, six days after the start of taking hydroxychloroquine, the virus had disappeared in three-quarters of people treated. READ MORE